8-K
filed September 28, 2023, 7:59 PM ET
ticker NERV
CIK 0001598646
other
confidence high
sentiment neutral
materiality 0.05
Minerva Neurosciences stockholders approve all proposals at 2023 annual meeting
Minerva Neurosciences, Inc.
- Directors David Kupfer and Jan van Heek elected with ~3.25M and ~3.37M votes, respectively.
- Equity plan amendment approved to increase authorized shares by 700,000; 3.28M for, 577K against.
- Advisory vote on named executive officer compensation passed with 3.74M for, 71K against.
- Ratification of Deloitte & Touche as auditor for FY2023 approved with 5.06M for.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Minerva Neurosciences, Inc. shareholders approved Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers at the 2023-09-27 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-09-27
Exact text from the filing
Proposal 3: Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers . The Company’s stockholders approved Proposal 3. The votes cast were as follows: For Against Abstain Broker Non-Votes 3,738,851 71,469 53,727 1,442,953
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Minerva Neurosciences, Inc. shareholders approved Election of Directors at the 2023-09-27 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-09-27
Exact text from the filing
The results of matters submitted to a stockholder vote at the Annual Meeting of Stockholders of Minerva Neurosciences, Inc. (the “Company”) held on September 27, 2023 (the “2023 Annual Meeting”) are as follows: Proposal 1: Election of Directors . Two nominees were elected to serve on the Company’s Board of Directors until the 2026 annual meeting of stockholders and until their successors are elected and qualified with the votes set forth below: Nominee For Withheld Broker Non-Votes David Kupfer 3,247,154 616,893 1,442,953 Jan van Heek 3,374,837 489,210 1,442,953
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Minerva Neurosciences, Inc. shareholders approved Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 at the 2023-09-27 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-09-27
Exact text from the filing
Proposal 4: Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 . The selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified with the votes set forth below: For Against Abstain Broker Non-Votes 5,061,117 11,600 234,283 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Minerva Neurosciences, Inc. shareholders approved Approval of Amendment to the Company’s Amended and Restated 2013 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 700,000 shares at the 2023-09-27 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-09-27
Exact text from the filing
Proposal 2: Approval of Amendment to the Company’s Amended and Restated 2013 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 700,000 shares. The Company’s stockholders approved Proposal 2. The votes cast were as follows: For Against Abstain Broker Non-Votes 3,283,310 576,673 4,064 1,442,953
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.